Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Battle of the stents: which drainage method wins for bile duct cancer?

NCT ID NCT06196164

Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study compares two endoscopic procedures—EUS-BD and ERCP-BD—for draining blocked bile ducts caused by cancers near the pancreas or bile duct. Forty adults with distal malignant bile duct obstruction will be randomly assigned to one of the two procedures. The main goal is to see which method keeps the bile duct open longer, with secondary measures including success rates, complications, and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic drainage procedure (EUS-BD or ERCP-BD)
What this could lead to
If successful, this study could show which drainage method works better for people with bile duct blockage from cancer, helping doctors choose the best option.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply to everyone. Both procedures carry risks like infection, bleeding, or stent failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jan 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age:18 years old or above; 2. Periampullary cancer/pancreatic cancer according to pathology or clinical judgment of more than 2 senior doctors; 3. Distal malignant bile duct obstruction (2cm away from the hepatic hilum); 4. Ultrasound evaluation shows that the accessible part of the bile duct has a width of ≥ 12mm; 5. The patient or family member is able to understand the research protocol and is willing to participate in this study, providing written informed consent. Exclusion Criteria: 1. Patients suffer from severe cardiovascular or pulmonary diseases who are unable to tolerate anesthesia or endoscopic examination; 2. Uncorrectable coagulation abnormalities or bleeding tendencies (INR\>1.5 or platelets\<50) × 109 /L); 3. There is a plan for subsequent surgical resection of the tumor, accompanied by severe infection or an expected survival period of less than 3 months; 4. Successful biliary drainage measures have been implemented, including but not limited to ERCP, ENBD, PTCD, and surgical procedures; 5. Previous surgical changes to the anatomical structure of the pancreas, gallbladder, stomach, and duodenum; 6. Pregnancy, lactation, or planned pregnancy; 7. Refusal to join or inability to provide informed consent; 8. Other researchers evaluated the unsuitability of enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholangiopancreatography, endoscopic retrograde are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

distal biliary tract carcinoma malignant pancreatic neoplasm obstructive jaundice periampullary adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cholangiopancreatography, endoscopic retrograde Endoscopic ultrasound-guided drainage Jaundice, obstructive

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.